195 related articles for article (PubMed ID: 23344961)
1. Topoisomerase IIβ deficiency enhances camptothecin-induced apoptosis.
Lin RK; Ho CW; Liu LF; Lyu YL
J Biol Chem; 2013 Mar; 288(10):7182-92. PubMed ID: 23344961
[TBL] [Abstract][Full Text] [Related]
2. Topoisomerase IIbeta mediated DNA double-strand breaks: implications in doxorubicin cardiotoxicity and prevention by dexrazoxane.
Lyu YL; Kerrigan JE; Lin CP; Azarova AM; Tsai YC; Ban Y; Liu LF
Cancer Res; 2007 Sep; 67(18):8839-46. PubMed ID: 17875725
[TBL] [Abstract][Full Text] [Related]
3. Differences in induction of p53, p21WAF1 and apoptosis in relation to cell cycle phase of MCF-7 cells treated with camptothecin.
Deptala A; Li X; Bedner E; Cheng W; Traganos F; Darzynkiewicz Z
Int J Oncol; 1999 Nov; 15(5):861-71. PubMed ID: 10536167
[TBL] [Abstract][Full Text] [Related]
4. The topoisomerase IIbeta circular clamp arrests transcription and signals a 26S proteasome pathway.
Xiao H; Mao Y; Desai SD; Zhou N; Ting CY; Hwang J; Liu LF
Proc Natl Acad Sci U S A; 2003 Mar; 100(6):3239-44. PubMed ID: 12629207
[TBL] [Abstract][Full Text] [Related]
5. Differential cytotoxic pathways of topoisomerase I and II anticancer agents after overexpression of the E2F-1/DP-1 transcription factor complex.
Hofland K; Petersen BO; Falck J; Helin K; Jensen PB; Sehested M
Clin Cancer Res; 2000 Apr; 6(4):1488-97. PubMed ID: 10778981
[TBL] [Abstract][Full Text] [Related]
6. Topoisomerase inhibitor camptothecin sensitizes mouse hepatocytes in vitro and in vivo to TNF-mediated apoptosis.
Hentze H; Latta M; Künstle G; Dhakshinamoorthy S; Ng PY; Porter AG; Wendel A
Hepatology; 2004 May; 39(5):1311-20. PubMed ID: 15122760
[TBL] [Abstract][Full Text] [Related]
7. Topoisomerase I inhibitor, camptothecin, induces apoptogenic signaling in human embryonic stem cells.
García CP; Videla Richardson GA; Romorini L; Miriuka SG; Sevlever GE; Scassa ME
Stem Cell Res; 2014 Mar; 12(2):400-14. PubMed ID: 24380814
[TBL] [Abstract][Full Text] [Related]
8. Topoisomerase degradation, DSB repair, p53 and IAPs in cancer cell resistance to camptothecin-like topoisomerase I inhibitors.
Tomicic MT; Kaina B
Biochim Biophys Acta; 2013 Jan; 1835(1):11-27. PubMed ID: 23006513
[TBL] [Abstract][Full Text] [Related]
9. Tipin functions in the protection against topoisomerase I inhibitor.
Hosono Y; Abe T; Higuchi M; Kajii K; Sakuraba S; Tada S; Enomoto T; Seki M
J Biol Chem; 2014 Apr; 289(16):11374-11384. PubMed ID: 24573676
[TBL] [Abstract][Full Text] [Related]
10. Differential GADD45, p21CIP1/WAF1, MCL-1 and topoisomerase II gene induction and secondary DNA fragmentation after camptothecin-induced DNA damage in two mutant p53 human colon cancer cell lines.
Goldwasser F; Bae I; Fornace AJ; Pommier Y
Oncol Res; 1996; 8(7-8):317-23. PubMed ID: 8938795
[TBL] [Abstract][Full Text] [Related]
11. Topoisomerase I inhibitor (camptothecin)-induced apoptosis in human gastric cancer cells and the role of wild-type p53 in the enhancement of its cytotoxicity.
Zhang ZW; Patchett SE; Farthing MJ
Anticancer Drugs; 2000 Oct; 11(9):757-64. PubMed ID: 11129739
[TBL] [Abstract][Full Text] [Related]
12. Camptothecin Efficacy to Poison Top1 Is Altered by Bisphenol A in Mouse Embryonic Fibroblasts.
Sonavane M; Sykora P; Andrews JF; Sobol RW; Gassman NR
Chem Res Toxicol; 2018 Jun; 31(6):510-519. PubMed ID: 29799191
[TBL] [Abstract][Full Text] [Related]
13. Camptothecin induces p53-dependent and -independent apoptogenic signaling in melanoma cells.
Rudolf E; Rudolf K; Cervinka M
Apoptosis; 2011 Nov; 16(11):1165-76. PubMed ID: 21809047
[TBL] [Abstract][Full Text] [Related]
14. Rad18 E3 ubiquitin ligase activity mediates Fanconi anemia pathway activation and cell survival following DNA Topoisomerase 1 inhibition.
Palle K; Vaziri C
Cell Cycle; 2011 May; 10(10):1625-38. PubMed ID: 21478670
[TBL] [Abstract][Full Text] [Related]
15. Target genes of Topoisomerase IIβ regulate neuronal survival and are defined by their chromatin state.
Tiwari VK; Burger L; Nikoletopoulou V; Deogracias R; Thakurela S; Wirbelauer C; Kaut J; Terranova R; Hoerner L; Mielke C; Boege F; Murr R; Peters AH; Barde YA; Schübeler D
Proc Natl Acad Sci U S A; 2012 Apr; 109(16):E934-43. PubMed ID: 22474351
[TBL] [Abstract][Full Text] [Related]
16. Topoisomerase I activity and sensitivity to camptothecin in breast cancer-derived cells: a comparative study.
Tesauro C; Simonsen AK; Andersen MB; Petersen KW; Kristoffersen EL; Algreen L; Hansen NY; Andersen AB; Jakobsen AK; Stougaard M; Gromov P; Knudsen BR; Gromova I
BMC Cancer; 2019 Nov; 19(1):1158. PubMed ID: 31783818
[TBL] [Abstract][Full Text] [Related]
17. Enhanced killing of cancer cells by poly(ADP-ribose) polymerase inhibitors and topoisomerase I inhibitors reflects poisoning of both enzymes.
Patel AG; Flatten KS; Schneider PA; Dai NT; McDonald JS; Poirier GG; Kaufmann SH
J Biol Chem; 2012 Feb; 287(6):4198-210. PubMed ID: 22158865
[TBL] [Abstract][Full Text] [Related]
18. Topoisomerase II inhibitor-induced apoptosis in thymocytes and lymphoma cells.
Kizaki H; Onishi Y
Adv Enzyme Regul; 1997; 37():403-23. PubMed ID: 9381984
[TBL] [Abstract][Full Text] [Related]
19. The role of the DNA mismatch repair system in the cytotoxicity of the topoisomerase inhibitors camptothecin and etoposide to human colorectal cancer cells.
Jacob S; Aguado M; Fallik D; Praz F
Cancer Res; 2001 Sep; 61(17):6555-62. PubMed ID: 11522654
[TBL] [Abstract][Full Text] [Related]
20. Deoxyguanosine enhances the cytotoxicity of the topoisomerase I inhibitor camptothecin by reducing the repair of double-strand breaks induced in replicating DNA.
Squires S; Ryan AJ; Strutt HL; Smith PJ; Johnson RT
J Cell Sci; 1991 Dec; 100 ( Pt 4)():883-93. PubMed ID: 1726104
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
